Sankyo, Ajinomoto to develop new diabetes drug, AJD101

By Lisa Kerner

Charlotte, N.C., Aug. 31 - Ajinomoto Co., Inc. granted Sankyo Co., Ltd., a Daiichi Sankyo group company, exclusive global rights to develop, manufacture and market Ajinomoto's glucose-lowering diabetes drug AJD101 and related compounds, according to a Daiichi Sankyo new release.

Sankyo will pay an up-front payment of ¥4.6 billion and milestone payments to Ajinomoto, which retains the right to manufacture a portion of the drug line.

Studies suggest that AJD101 activates the insulin-signaling pathway to stimulate glucose uptake, according to the release.

The two Tokyo-based pharmaceutical companies co-marketed the anti-hyperglycemic tablets Fastic in December 2001.

The International Diabetes Federation estimates the number of diabetes patients will increase to 333 million by 2025.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.